It has invested in high-level expertise, personnel, and facilities globally, with the goal of rapid transition into the launch of its innovative cell and gene therapy (CGT) manufacturing platform.
The developer has boosted its senior leadership team with several new appointments, including three directors, to support further growth and push the commercialization of its platform, along with further expanding its Science Advisory Board (SAB), appointing CGT experts, Isabelle Rivière and Jason Bock.
It has also opened a new facility in Princeton, New Jersey, US and will be opening a new technology center, in Cambridge, UK.
New hires
The company outlined how it has made new hires within teams across digital infrastructure, data analytics, software, manufacturing, and quality.
Kale Feeder and Lindsey Clarke have joined Ori as directors of business development. Feeter was formerly at Cytiva and Thermo Fisher while Clarke joins from Bio-Techne, having previously been at Miltenyi Biotec. In addition, Quentin Vicard has been appointed as director of product management – he was previously with Sartorius. Brian Macauley has been recruited as cloud platform lead and Claire Horlock has come on board as principal scientist, joining from Autolus.
In terms of the additions to the SAB, Ori said Isabelle Rivière brings 25 years of CGT experience, including from the Memorial Sloan-Kettering Cancer Center (MSKCC), where she is currently director of the cell therapy and cell engineering laboratory. She is also a co-founder of Juno Therapeutics, a board member of the American Society of Gene and Cell Therapy (ASGCT) and past board member of the Alliance for Regenerative Medicine (ARM). Jason Bock, CEO of the newly formed cell therapy manufacturing center (CTMC), a joint venture between MD Anderson and National Resilience, also adds 20 years biotech experience developing and bringing therapeutics to the market.